Search results for "COPD"

showing 10 items of 483 documents

Roflumilast Prevents the Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model

2015

Fibrotic remodeling is a process common to chronic lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, acute respiratory distress syndrome and asthma. Based on preclinical studies phosphodiesterase 4 (PDE4) inhibitors may exhibit beneficial anti-inflammatory and anti-remodeling properties for the treatment of these respiratory disorders. Effects of PDE4 inhibitors on changes in the lung metabolome in models of pulmonary fibrotic remodeling have not yet been explored. This work studies the effects of the PDE4 inhibitor roflumilast on changes in the lung metabolome in the common murine model of bleomycin-induced lung fibrosis by nuclear magnetic resonance (…

CyclopropanesMalePathologymedicine.medical_specialtyMagnetic Resonance SpectroscopyPulmonary Fibrosislcsh:MedicineAminopyridinesPharmacologyBiologyBleomycinBleomycinMicechemistry.chemical_compoundFibrosisPulmonary fibrosismedicineMetabolomeAnimalsRespiratory systemlcsh:ScienceLungRoflumilastCOPDMultidisciplinaryLunglcsh:Rmedicine.diseaserespiratory tract diseasesMice Inbred C57BLDisease Models Animalmedicine.anatomical_structurechemistryBenzamidesMetabolomelcsh:QResearch Articlemedicine.drugPLOS ONE
researchProduct

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

2009

After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may become the first agent in this class to be approved for patient treatment worldwide. Within the PDE family of 11 known isoenzymes, roflumilast is selective for PDE4, showing balanced selectivity for subtypes A-D, and is of high subnanomolar potency. The active principle of roflumilast in man is its dichloropyridyl N-oxide metabolite, which has similar potency as a PDE4 inhibitor as the parent compound. The long half-life and high potency of this metabolite allows for once-daily, oral administration of a single, 500…

CyclopropanesPulmonary and Respiratory MedicinePhosphodiesterase Inhibitorsmedicine.drug_classDrug Evaluation PreclinicalAdministration OralAminopyridinesInflammationPharmacologyPulmonary Disease Chronic ObstructiveCOPD; Inflammation; Oral therapy; Phosphodiesterase 4; Preclinical pharmacology; RoflumilastBronchodilatormedicineAnimalsHumansCOPDPharmacology (medical)RoflumilastPhosphodiesterase 4InflammationCOPDLungOral therapybusiness.industryAnti-Inflammatory Agents Non-SteroidalBiochemistry (medical)medicine.diseasePulmonary hypertensionObstructive lung diseasemedicine.anatomical_structureTolerabilityBenzamidesImmunologyPhosphodiesterase 4 InhibitorsPreclinical pharmacologymedicine.symptombusinessRoflumilastmedicine.drug
researchProduct

Bronchial microbiome, PA biofilm-forming capacity and exacerbation in severe COPD patients colonized by P. aeruginosa

2017

Aim: The bronchial microbiome of severe chronic obstructive pulmonary disease patients colonized by Pseudomonas aeruginosa was analyzed using 16S rRNA gene sequencing to identify differences related to biofilm-forming capacity. Patients & methods: Patient sputum samples from 21 patients were studied. Results: Statistically significant differences related to biofilm-forming capacity were only found for genera with relative abundances <1%, and Fusobacterium was over-represented when biofilm-forming capacity was high. Genera with relative abundances >50% which increased from baseline were observed in 10/14 exacerbations, but corresponded to Pseudomonas only in three episodes, while …

DNA Bacterial0301 basic medicineMicrobiology (medical)Lung microbiomeExacerbation030106 microbiologyBronchiSevere copdmedicine.disease_causeDNA RibosomalMicrobiologyMicrobiologyPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineRNA Ribosomal 16SmedicineHumansPseudomonas InfectionsMicrobiomebiologyPseudomonas aeruginosaMicrobiotaPseudomonasSputumBiofilmSequence Analysis DNAbiology.organism_classification030228 respiratory systemBiofilmsPseudomonas aeruginosaSputummedicine.symptomFuture Microbiology
researchProduct

Telerehabilitation for COPD Patients across Sectors: Using Technology to Promote Cooperation among Healthcare Professionals

2011

A telerehabilitation programme for patients with chronic obstructive pulmonary lung disease has been developed. Aim: The aim of the paper is to explore how telerehabilitation technology influences cooperation and coordination between healthcare professionals in the Telekat network. Theory: Network theory has been applied. Methods: A triangulation of data collection techniques such as documentary materials, participant observations (n=163 hours), and qualitative interviews (n=24) has been used in a case study of the Telekat project. Findings: Telerehabilitation technologies influences cooperation and coordination between healthcare professionals in themes like: interdisciplinary decision mak…

Data collectiongenetic structuresHealth professionalsbusiness.industryCopd patientsQualitative interviewseducationNursingLung diseaseTelerehabilitationFacilitatorMedicinebusinessMutual learning
researchProduct

Emergence of Aspergillus fumigatus azole resistance in azole-naïve patients with chronic obstructive pulmonary disease and their homes.

2017

Azole-resistant Aspergillus fumigatus (ARAF) has been reported in patients with chronic obstructive pulmonary disease (COPD) but has not been specifically assessed so far. Here, we evaluated ARAF prevalence in azole-naïve COPD patients and their homes, and assessed whether CYP51A mutations were similar in clinical and environmental reservoirs. Sixty respiratory samples from 41 COPD patients with acute exacerbation and environmental samples from 36 of these patient's homes were prospectively collected. A. fumigatus was detected in respiratory samples from 11 of 41 patients (27%) and in 15 of 36 domiciles (42%). Cyp51A sequencing and selection on itraconazole medium of clinical (n = 68) and e…

Drug Resistance Fungal -- genetics0301 basic medicineAzolesMaleAntifungal AgentsExacerbationMESH: Fungal Proteins/isolation & purification[SDV]Life Sciences [q-bio]Colony Count MicrobialAspergillus fumigatusMESH: Aspergillus fumigatus/drug effectsMESH: Cytochrome P-450 Enzyme System/drug effectsMESH: GenotypePulmonary Disease Chronic ObstructivedwellingCytochrome P-450 Enzyme SystemGenotypePulmonary Disease Chronic Obstructive -- microbiologyPrevalenceProspective Studieschemistry.chemical_classificationMESH: AgedCOPDAzole-resistanceMESH: Middle AgedbiologyMESH: Drug Resistance Fungal/geneticsMold environmental exposureSciences bio-médicales et agricolesMiddle Aged3. Good healthMESH: Pulmonary Disease Chronic Obstructive/microbiology*MESH: Housing[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAir Pollution IndoorAcute DiseaseDisease ProgressionMESH: Acute DiseaseMESH: Cytochrome P-450 Enzyme System/isolation & purificationMESH: Disease ProgressionFemalemedicine.drugmedicine.medical_specialtyEnvironmental EngineeringGenotypeItraconazoleMESH: Fungal Proteins/drug effects030106 microbiologyAspergillus fumigatus -- drug effects -- genetics -- isolation & purificationMESH: Azoles/pharmacology*Fungal Proteins -- drug effects -- isolation & purificationchronic obstructive pulmonary diseaseMicrobiologyFungal Proteins03 medical and health sciencesazole resistanceMESH: Air Pollution Indoor/analysis*Drug Resistance FungalInternal medicinemedicineCOPDHumansMESH: Aspergillus fumigatus/geneticsDwellingMESH: Colony Count MicrobialMESH: PrevalenceAgedAspergillusMESH: HumansAspergillus fumigatusAzoles -- pharmacologyelectrostatic dust collectorPublic Health Environmental and Occupational Healthmold environmental exposureElectrostatic dust collectorBuilding and Constructionmedicine.diseasebiology.organism_classificationMESH: MaleMESH: Prospective StudieschemistryCytochrome P-450 Enzyme System -- drug effects -- isolation & purificationHousingAzoleARAFMESH: Aspergillus fumigatus/isolation & purification*Antifungal Agents -- pharmacologyMESH: Antifungal Agents/pharmacology*MESH: FemaleAir Pollution Indoor -- analysisIndoor air
researchProduct

Lung deposition of extrafine inhaled corticosteroid (ICS)-containing fixed combinations drug in COPD patients using Functional Respiratory Imaging (F…

2018

Introduction: FRI is a novel computational fluid dynamics (CFD)-based technique using formulation profile and patients lung CT scan to simulate aerosol deposition. Aims and objectives: To evaluate lung deposition of pressurized metered dose inhaler (pMDI) extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G Trimbow®) with pMDI extrafine BDP/FF (Foster®) pMDI and compared them with reference gamma scintigraphy data. Methods: FRI was used to assess, in silico, the deposition of pMDI combination products (BDP/FF/G and BDP/FF) in 20 moderate to severe COPD patients. FRI combined high-resolution lung CT scans of each patient with in silico computational flow simulati…

DrugInhalationLung depositionmedicine.diagnostic_testmedicine.drug_classCopd patientsbusiness.industrymedia_common.quotation_subjectBeclometasone dipropionaterespiratory systemScintigraphy030226 pharmacology & pharmacyMetered-dose inhaler03 medical and health sciences0302 clinical medicine030228 respiratory systemmedicineCorticosteroidNuclear medicinebusinessmedia_commonmedicine.drugAirway pharmacology and treatment
researchProduct

Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.

2020

Inhalation therapy allows conveying drugs directly into the airways. The devices used to administer inhaled drugs play a crucial role in the management of obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). To ensure high bronchial deposition of the drug, a device should deliver a high proportion of fine particles, be easy to use, and provide constant and accurate doses of the active substance. Nowadays, four different types of inhalers are widely used: nebulizers, dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and soft mist inhalers (SMIs). Nebulizers can be used by patients unable to use other inhalers. However, they require l…

Drugmedicine.medical_specialtyRespiratory TherapyRespimatmedia_common.quotation_subjectSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologyMDI03 medical and health sciencesRoute of administrationPulmonary Disease Chronic Obstructive0302 clinical medicineAsthma COPD DPI MDI Nebulizer RespimatAdministration InhalationInternal MedicinemedicineCOPDHumans030212 general & internal medicineMetered Dose InhalersIntensive care medicineAsthmamedia_commonCOPDInhalationbusiness.industryInhalerNebulizers and VaporizersNebulizerEquipment Designmedicine.diseaseAsthma; COPD; DPI; MDI; Nebulizer; RespimatAsthmaRespimatDPINebulizerbusinessEuropean journal of internal medicine
researchProduct

Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD.

2014

Background In models of COPD, environmental stressors induce innate immune responses, inflammasome activation and inflammation. However, the interaction between these responses and their role in driving pulmonary inflammation in stable COPD is unknown. Objectives To investigate the activation of innate immunity and inflammasome pathways in the bronchial mucosa and bronchoalveolar lavage (BAL) of patients with stable COPD of different severity and control healthy smokers and non-smokers. Methods Innate immune mediators (interleukin (IL)-6, IL-7, IL-10, IL-27, IL-37, thymic stromal lymphopoietin (TSLP), interferon γ and their receptors, STAT1 and pSTAT1) and inflammasome components (NLRP3, NA…

EXPRESSIONMaleINTERLEUKIN-6InflammasomesCOPD PathologyChronic Obstructive Pulmonary DiseaseRespiratory SystemImmunity NLRP3 COPDBronchiReceptors Cell SurfaceRespiratory MucosaPULMONARYInterferon-gammaPulmonary Disease Chronic ObstructiveMARKERSThymic Stromal LymphopoietinSPUTUMNLR Family Pyrin Domain-Containing 3 ProteinCytokine Receptor gp130Humans1506HMGB1 ProteinAdaptor Proteins Signal TransducingAgedScience & TechnologyRECEPTORInterleukinsSmoking1103 Clinical SciencesMiddle AgedInterleukin-1 Receptor-Like 1 ProteinImmunity InnateInnate Immunityrespiratory tract diseasesANTIINFLAMMATORY CYTOKINESTAT1 Transcription FactorCase-Control StudiesT-CELLSASTHMACytokinesFemaleCOPD Pathology Innate ImmunityCarrier ProteinsLife Sciences & BiomedicineBronchoalveolar Lavage FluidSMOKERSThorax
researchProduct

Pulmonary hypertension in COPD and lung transplantation: Timing and procedures

2014

The prevalence of pulmonary hypertension (PH) in the general chronic obstructive pulmonary disease (COPD) population is undefined because stable COPD patients do not routinely undergo screening echocardiogram and right heart catheterization. Most studies published on this topic are focused on a highly selected group of patients with moderate to severe disease awaiting lung transplantation, since hemodynamic data from cardiac catheterization are part of the standard transplant evaluation. In a very recent article, Hurdman et al. studied the characteristics and outcomes, with a particular focus on mortality, of extensively phenotyped, consecutive patients with PH-COPD over a 9-year period. Th…

Emphysema; Hypertension; Lung diseases; Lung transplantation; Obstructive; Pulmonary; Respiratory function testsEmphysemaLung transplantationObstructiveHypertensiontransplantation COPD pulmonary hypertensionPulmonarySettore MED/10 - Malattie Dell'Apparato RespiratorioRespiratory function testsLung diseases
researchProduct

COPD classification methods and informativeness on mortality: Contrasting evidences

2013

Understanding whether the ABCD GOLD classification method is informative with respect to the spirometric classification of severity in predicting mortality of patients with chronic obstructive pulmonary disease (COPD) is subject of debate. The results of a study performed on a sample of the Norwegian population (HUNT2) were recently published. Such data showed the inferiority of ABCD classification in predicting mortality compared to the spirometric classification, which was considered the gold standard up to the 2011 version of GOLD guidelines. This result is not in line with the results of other studies that have shown the equivalence of the two classifications. The new GOLD classificatio…

EpidemiologyCOPD guidelines lung functionPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioChronic obstructive-pulmonary diseaseLung diseasesChronic obstructive; Chronic obstructive-pulmonary disease; Epidemiology; Lung diseases; Pulmonary diseaseChronic obstructive
researchProduct